摘要
目的:考察磺酸基巯基壳聚糖微球(简称STCM)的体外降解特性。方法:分别于10和50μg.mL-1的溶菌酶溶液(pH 7.4)中考察微球在1,2,4及8周时的降解情况;分别于0.1,0.2,0.5 mol.L-1的NaCl浓度溶液(溶菌酶浓度为10μg.mL-1,pH 7.4)中考察微球在不同离子浓度中的降解情况,对照组为去离子水。结果:STCM在10μg.mL-1溶菌酶溶液中的降解速度为每周3.9%,截止到第8周,有31.2%被降解;在50μg.mL-1的溶菌酶溶液里微球降解率较10μg.mL-1的有所下降;随着NaCl浓度的增加,第4周以后微球降解速率反而有所下降,对照组与0.1 mol.L-1的NaCl溶液中的降解率无显著差别(P>0.05)。结论:初步实验证实STCM在体外具有缓慢降解的特性,初步符合临床介入治疗对栓塞剂降解速度的要求,提示其具有潜在的医用前景。
Objective： To investigate the degradation property of sulfonic-thiol-chitosan microspheres （STCM） in vitro. Methods：The degradation ratios of STCM in 10 and 50 μg·mL-1 lysozyme solution （pH 7.4） were determined on week 1,2,4 and 8 respectively;the degradation ratios of STCM in 0.1,0.2,0.5 mol L-1 sodi- um chloride solution containing 10 μg·mL-1 lysozyme （pH 7.4）were determined on week 1,2,4 and 8, respective- ly; deionized water was used as control. Results：The degradation ratio of STCM in 10 μg·mL-1 lysozyme solution was 3.9% per week, and about 31.2% were degraded up to week 8. The degradation ratio in 50 μg·mL-1 lyso- zyme solution was lower than in 10 μg·mL-1 lysozyme solution. The degradation ratio decreased with increasing concentration of sodium chloride solution after 4 weeks ,while the degradation ratio in the control group showed little difference with 0.1 mol. L-1 sodium chloride solution（ P 〉 0.05 ）. Conclusion ：This preliminary test confirmed that the degradation ratio of STCM was slow enough in vitro to meet the requirements for embolic agents applied in clini- cal intervention treatment, and could be possibly used in medical field.
出处
《中国新药杂志》
CAS
CSCD
北大核心
2013年第15期1831-1832,1848,共3页
Chinese Journal of New Drugs
基金
福建省自然科学基金(2010J01208)
关键词
磺酸基巯基壳聚糖
微球
栓塞剂
介入治疗
sulfonic-thiol-chitosan
microspheres
embolization agents
interventional treatment
